Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

TCT 2021 | Healthcare utilization & end of life outcomes in patients receiving CAR-T

Connor Johnson • 5 Feb 2021
TCT 2021
Lymphoma

Connor Johnson, MD, Massachusetts General Hospital & Harvard Medical School, Boston, MA, outlines the results of a retrospective analysis evaluating the impact of CAR T-cell therapy on healthcare utilization and end-of-life outcomes. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Connor Johnson

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
Association between baseline PROs & complications of HSCT 3:25
Association between baseline PROs & complications of HSCT
Connor Johnson • 5 Feb 2021

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals